Inovio Pharmaceuticals Aktie News

Aktie
WKN:  A400EJ ISIN:  US45773H4092 US-Symbol:  INO Branche:  Biotechnologie Land:  USA
1,47 €
-0,01 €
-0,68%
02.01.26
Depot/Watchlist
Marktkapitalisierung *
70,23 Mio. €
Streubesitz
61,67%
KGV
-0,75
Index-Zuordnung
-

Inovio Pharmaceuticals News

03.07.25 - PR Newswire
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Pricing of $25 Million Public Offering PR Newswire
02.07.25 - PR Newswire
INOVIO Announces Proposed Public Offering
INOVIO Announces Proposed Public Offering PR Newswire
13.05.25 - PR Newswire
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
30.04.25 - PR Newswire
INOVIO to Present at Upcoming Scientific and Investor Conferences
INOVIO to Present at Upcoming Scientific and Investor Conferences PR Newswire
29.04.25 - PR Newswire
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 PR Newswire
09.04.25 - PR Newswire
INOVIO to Present at Upcoming Scientific Conferences
INOVIO to Present at Upcoming Scientific Conferences PR Newswire
18.03.25 - PR Newswire
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights PR Newswire
13.03.25 - PR Newswire
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
INOVIO Announces Promising Interim Results from Ongoing Proof-​of-Concept Clinical Trial of DNA-​Encoded Monoclonal Antibodies (DMAbs) for COVID-19 PR Newswire
12.03.25 - PR Newswire
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 PR Newswire
12.02.25 - PR Newswire
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications PR Newswire
10.02.25 - PR Newswire
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-​Oncology (AACR-IO) Conference PR Newswire
29.01.25 - PR Newswire
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire
09.01.25 - PR Newswire
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments PR Newswire

Newssuche

Videos

newspaper
02.01.26 -4,63%
Technical Trading: Gold Long saisonal
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »